Constance Weber

Clinical outcomes of the PAUL glaucoma implant in primary open-angle and pseudoexfoliative glaucoma eyes after failed glaucoma surgeries.

In conclusion, the PGI demonstrated significant IOP reduction and decreased need for medication in both POAG and PEXG patients, with no major differences between the two groups at 12 months.

Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.

PGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.

Clinical outcomes of the EyeWatch system: three-year results.

Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.

Comparing the use of Tutopatch® pericardium with Tutoplast® fascia lata in the context of PAUL® glaucoma implant surgery: an anterior segment OCT study.

This study shows that AS-OCT is a useful method for comparing different patch materials after PGI surgery.

Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.

European glaucoma care shows marked regional differences in surgical practices and referral timeliness. Frequent late referrals are associated with advanced disease, highlighting a need for improved early intervention to prevent vision loss.